Business Wire

OR-RADISYS

19.3.2020 09:02:04 CET | Business Wire | Press release

Share
Radisys Unveils Engage Video Assistant – World’s First AI-Powered Video Bot

Radisys® Corporation , a global leader of open telecom solutions, today announced the global availability of the Radisys Engage Video Assistant (EVA), the world’s first app-less AI-powered 3-in-1 (video, voice, text) bot for digital customer interactions. The EVA empowers customer support, sales and marketing teams to significantly enhance the customer experience by delivering greater personalization that drives customer acquisition, retention, and satisfaction with the cost savings of automation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005010/en/

Customers can access the EVA to interact visually with sales professionals, subject-matter-experts, brand ambassadors, brand influencers, and customer care agents – simply by dialing a regular customer support number, using a Video over LTE (ViLTE) capable 4G/LTE or 5G smartphone, or by clicking a link on the website with no download required. The EVA can also be integrated with mobile apps. EVA’s powerful AI engine determines the customer’s intent and delivers the right information, and when required it supports the transition of the bot interaction to live agents to ensure a consistent and seamless customer experience and the most cost-effective use of live agents.

As a white label solution, the EVA offers service providers a platform with flexible deployment options, either in-network or accessible from the cloud. It enables new revenue streams by providing Video Call Bot-as-a-Service for call centers, SMBs and large enterprise customers, and it can reduce contact centers’ costs by automating interactions – like how-to interactions or sophisticated troubleshooting – that are underserved by voice or text bots alone.

Key Takeaways

  • Today’s technologies provide tools that can control and improve the digital customer experience by creating self-service customer engagement. However, while chatbots, voice-enabled digital assistants, and other similar automation technologies are enabling businesses to achieve cost-effective scalability and agility, they lack a human touch needed for a satisfactory customer experience.
  • The Engage Video Assistant application allows service providers, call centers and businesses to:
  • Humanize existing calls and interactive mobile or voice apps with video while maintaining an authentic visual brand persona.
  • Create video FAQs for new product launches or common customer support issues.
  • Enhance existing bots and cumbersome interactive voice response (IVR) solutions.
  • Scale influencers and brand ambassadors to unprecedented levels through personalized customer interactions.
  • Engage customers at their time of choice – day or night, weekday or holiday – with personalized video interactions.
  • Engage Video Assistant is deployed by Reliance Jio, the world’s largest VoLTE service provider, serving 370 million subscribers in India and helping its business customers to enhance their customer service, reduce their customer support cost, and enhance agent productivity.

“Radisys’ app-less calling experience enables businesses and service providers to offer an unprecedented in-call experience to their customers,” said Alan Quayle, independent consultant and founder, TADHack and TADHack Summit. “Its ease of integration lowers customer support costs; and improves productivity by helping customers get what they need faster, with a personal touch.”

“Video is a proven way to create greater immersion, increase click-throughs, and convert connections to purchases,” said Al Balasco, vice president, communications solutions, Radisys. “Engage Video Assistant is the first digital engagement bot application to combine video, voice and text seamlessly to provide ubiquitous and customizable brand and customer service reach for B2B and B2C customer interactions anywhere, anytime.”

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye